Bimagrumab (BYM338) · 10 mg
Published- batch · LOT
- B-2026-BIMA-10-001
- Laboratory
- MZ Biolabs
- purity
- 99.92%
- Test date
- 04.08.2026
Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
Not a peptide but a full monoclonal antibody: it blocks the activin receptor and switches off myostatin and activin signals in one move. It has been studied for muscle mass in clinical phases.
Selected size: 10 mg
10 mg analysis published
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Early studies (phase I) | 210–700 mg IV every 4 weeks | Starting dose |
| Main phase II regimen | 10 mg/kg (max 1200 mg) IV every 4 weeks | Increase if needed |
| Later studies | 10–30 mg/kg IV every 12 weeks | Maximum in this schedule |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Diarrhea | Adults with type 2 diabetes and overweight or obesity, intravenous, 48 weeks | Reported; no frequency given | [1] |
| Muscle spasms | The same participants | Reported; no frequency given | [1] |
| Pancreatitis (serious event) | The bimagrumab arm of the same trial | Occurred in the bimagrumab arm; serious events occurred in both arms; occurrence does not establish causation | [1] |
FAQ
Find answers to questions about Bimagrumab (BYM338) and related materials.
Bimagrumab (BYM338) is not a peptide. It is a fully human monoclonal antibody of the IgG class (about 150 kDa), selected from the HuCAL library in a Novartis–MorphoSys collaboration. In size, pharmacokinetics and handling it resembles no short peptide in this catalog — worth keeping in mind when working with it.
Source / documentationIt blocks the type II activin receptors (ActRIIA/ActRIIB) — the shared "gate" for several muscle-braking signals at once: myostatin, activin A and GDF-11. Blocking the receptor rather than a single ligand switches off the whole group in one move; that is why bimagrumab has been studied for muscle mass and metabolism in clinical phases.
Source / documentationACE-083 intercepts ligands locally, in the muscle it was injected into. Bimagrumab acts systemically — through the receptor, across the whole body. These are two different philosophies for one target: a local trap versus a systemic blocker.
Source / documentationIn clinical studies it was given by intravenous infusion once every 4 weeks (phase I used 210–700 mg) — a clinical-centre format, not home injections. Regimens are in the dosing guide on this page.
Source / documentationThere is no complete safety profile for use outside studies, so an honest exhaustive list cannot be compiled. A full review of the known data is in the bimagrumab monograph in our wiki.
Source / documentationKeep the dry powder in a dry, dark place at a low temperature; once dissolved, store it in the refrigerator and do not freeze it again. Details are in the bimagrumab guide on this page.
Source / documentationYou can buy bimagrumab right on this page of our store: current prices and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. The product ships with the certificate of analysis (COA) for its exact batch.
Source / documentationCertificates shown: 1
Share your experience
No reviews yet. Tell others what you think of this product.
Bimagrumab (BYM338) is not a peptide. It is a fully human monoclonal antibody of the IgG class (about 150 kDa), selected from the HuCAL library in a Novartis–MorphoSys collaboration. In size, pharmacokinetics and handling it resembles no short peptide in this catalog — worth keeping in mind when working with it.
What it does: it blocks the type II activin receptors (ActRIIA/ActRIIB) — the shared "gate" for several muscle-braking signals at once: myostatin, activin A and GDF-11. Blocking the receptor rather than a single ligand switches off the whole group in one move; that is why bimagrumab has been studied for muscle mass and metabolism in clinical phases.
How it differs from ACE-083: that one intercepts ligands locally in the muscle, while bimagrumab acts systemically through the receptor. In clinical studies it was given by intravenous infusion once every 4 weeks (phase I used 210–700 mg) — a clinical-centre format, not home injections. Regimens are in the dosing guide; the full line is in the myostatin/activin category.
Every batch is purity-tested by HPLC, and the certificate of analysis (COA) for your exact batch is in our COA archive. Keep the dry powder in a dry, dark place at a low temperature, and the dissolved solution in the refrigerator.